{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:54:27Z","timestamp":1791561267674,"version":"4.3.4"},"reference-count":110,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Patients with advanced hepatocellular carcinoma (HCC) have several systemic treatment options. There are many known risk factors for HCC, and although some, such as hepatitis C, are now treatable, others are not. For example, metabolic dysfunction-related chronic liver disease is increasing in incidence and has no specific treatment. Underlying liver disease, drug resistance, and an increasing number of treatment options without specific biomarkers are all challenges in selecting the best treatment for each patient. Conventional chemotherapy is almost never used for advanced-stage disease, which instead is treated with immunotherapy, tyrosine kinase inhibitors, and VEGF inhibitors. Immune checkpoint inhibitors targeting various receptors have been or are currently undergoing clinical evaluation. Ongoing trials with three-drug regimens may be the future of advanced-stage HCC treatment. Other immune-modulatory approaches of chimeric antigen receptor-modified T cells, bispecific antibodies, cytokine-induced killer cells, natural killer cells, and vaccines are in early-stage clinical trials. Targeted therapies remain limited for HCC but represent an area of potential growth. As we shift away from first-line sorafenib for advanced HCC, clinical trial control arms should comprise a standard treatment other than sorafenib, one that is a better comparator for advancing therapies.<\/jats:p>","DOI":"10.3390\/ijms25021259","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T11:04:57Z","timestamp":1705662297000},"page":"1259","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-152X","authenticated-orcid":false,"given":"Narayanan","family":"Sadagopan","sequence":"first","affiliation":[{"name":"MedStar Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwu Ruth","family":"He","sequence":"additional","affiliation":[{"name":"MedStar Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jjco\/27.5.321","article-title":"Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma","volume":"27","author":"Nagahama","year":"1997","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2018181494","article-title":"Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"key":"ref_3","unstructured":"Hoshida, Y. (2023, August 23). Radiological Diagnosis and Characterization of HCC, Hepatocellular Carcinoma: Translational Precision Medicine Approaches, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553760\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_5","unstructured":"(2023, November 01). NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines) Hepatocellular Carcinoma Version 2. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hcc.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/978-3-0348-0837-8_16","article-title":"The role of inflammation and liver cancer","volume":"816","author":"Bishayee","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The Burden of Primary Liver Cancer and Underlying Etiologies from 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_8","unstructured":"(2023, August 25). International Agency on Research on Cancer: Liver. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/11-Liver-fact-sheet.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3748\/wjg.v25.i13.1550","article-title":"Hepatocellular carcinoma surveillance: An evidence-based approach","volume":"25","author":"Harris","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ijc.1498","article-title":"Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma","volume":"94","author":"Nies","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_15","first-page":"8","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1078-0432.CCR-21-3807","article-title":"Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial","volume":"28","author":"Verset","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S808","DOI":"10.1016\/j.annonc.2022.08.031","article-title":"LBA34\u2014Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)","volume":"33","author":"Finn","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: A phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","article-title":"Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study","volume":"40","author":"Qin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"616837","DOI":"10.3389\/fimmu.2021.616837","article-title":"Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment","volume":"12","author":"Bourhis","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): A randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): A multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S1402","DOI":"10.1016\/j.annonc.2022.08.033","article-title":"LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma","volume":"33","author":"Qin","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_31","unstructured":"(2023, August 23). Tislelizumab. Available online: https:\/\/www.beigene.com\/our-science-and-medicines\/tislelizumab\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/annonc\/mdy101","article-title":"Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma","volume":"29","author":"Qin","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_33","unstructured":"(2023, August 24). Study of ADI-PEG 20 versus Placebo in Subjects with High Arginine Level and Unresectable Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05317819."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3389\/fimmu.2019.02525","article-title":"Liver-Mediated Adaptive Immune Tolerance","volume":"10","author":"Zheng","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1200\/JCO.22.00972","article-title":"Nivolumab Plus Cabozantinib with or without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial","volume":"41","author":"Yau","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_37","unstructured":"(2023, August 23). Cabozantinib Combined with Ipilimumab\/Nivolumab and TACE in Patients with Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04472767."},{"key":"ref_38","unstructured":"(2023, August 23). Safety and Efficacy of Coformulated Pembrolizumab\/Quavonlimab (MK-1308A) in Combination with Lenvatinib (E7080\/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04740307."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1200\/JCO.2023.41.16_suppl.4010","article-title":"Results from the MORPHEUS-liver study: Phase Ib\/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)","volume":"41","author":"Finn","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","unstructured":"(2023, August 23). A Study Evaluating Atezolizumab and Bevacizumab, with or without Tiragolumab, in Participants with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05904886."},{"key":"ref_42","unstructured":"(2023, August 23). Trial of Atezolizumab and Bevacizumab with SRF388 or Placebo in Patients with Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05359861."},{"key":"ref_43","unstructured":"(2023, August 23). Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma Receiving First-Line Systemic Therapy (TRIPLET), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05665348."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"TPS636","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS636","article-title":"RELATIVITY-106: A phase 1\/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC)","volume":"4","author":"Sangro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_45","unstructured":"(2023, August 23). A Study of Nivolumab and Relatlimab in Combination with Bevacizumab in Advanced Liver Cancer (RELATIVITY-106), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05337137."},{"key":"ref_46","unstructured":"(2023, August 23). A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined with Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05363722."},{"key":"ref_47","unstructured":"(2023, August 23). A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients with Advanced HCC, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04948697."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2147\/DDDT.S304857","article-title":"Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib\/II Study","volume":"15","author":"Li","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_49","unstructured":"(2023, August 23). A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination with FOLFOX4 in Subjects with Advanced HCC Who Have Never Received Prior Systemic Treatment, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03605706."},{"key":"ref_50","unstructured":"(2023, August 24). A Study of Nofazinlimab (CS1003) in Subjects with Advanced Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04194775."},{"key":"ref_51","unstructured":"(2023, August 24). A Phase III Clinical Trial of AK105 Injection Combined with Anlotinib Hydrochloride Capsules versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04344158."},{"key":"ref_52","unstructured":"(2023, August 24). Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination with Lenvatinib for Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04401800."},{"key":"ref_53","unstructured":"(2023, August 24). A Study to Compare the Effectiveness and Safety of IBI310 Combined with Sintilimab versus Sorafenib in the First-line Treatment of Advanced HCC, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04720716."},{"key":"ref_54","unstructured":"(2023, August 24). A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated with Atezolizumab and Bevacizumab (IMbrave251), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04770896."},{"key":"ref_55","unstructured":"(2023, August 24). Sorafenib and Nivolumab in Treating Participants with Unresectable, Locally Advanced or Metastatic Liver Cancer, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03439891."},{"key":"ref_56","unstructured":"(2023, August 24). Sorafenib Tosylate and Pembrolizumab in Treating Patients with Advanced or Metastatic Liver Cancer, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03211416."},{"key":"ref_57","unstructured":"(2023, August 24). A Study of Nivolumab in Combination with Ipilimumab in Participants with Advanced Hepatocellular Carcinoma (CheckMate 9DW), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04039607."},{"key":"ref_58","unstructured":"(2023, August 24). Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04710641."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","article-title":"MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C\/EBP-\u03b1, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial","volume":"26","author":"Sarker","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1615817","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: A randomized multicenter Phase IIb trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_61","unstructured":"(2023, August 24). Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs. Sorafenib Alone (PHOCUS), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02562755."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2015.05.055","article-title":"T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice","volume":"149","author":"Dargel","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3389\/fimmu.2016.00690","article-title":"Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma","volume":"7","author":"Jiang","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1078-0432.CCR-16-1203","article-title":"Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_67","first-page":"219","article-title":"High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma","volume":"52","author":"Wei","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1440-1746.2006.04271.x","article-title":"Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma","volume":"21","author":"Nakamura","year":"2006","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-04-1487","article-title":"Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma","volume":"11","author":"Miura","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","article-title":"Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4132\/jptm.2015.10.09","article-title":"Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma","volume":"50","author":"Sung","year":"2016","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_72","unstructured":"(2023, August 24). GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05003895."},{"key":"ref_73","unstructured":"(2023, August 24). ECT204 T-Cell Therapy in Adults with Advanced HCC (ARYA3), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04864054."},{"key":"ref_74","unstructured":"(2023, August 24). Study of ET140203 T Cells in Adults with Advanced Hepatocellular Carcinoma (ARYA-1), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04502082."},{"key":"ref_75","unstructured":"(2023, August 24). AFPc332T in Advanced HCC, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03132792."},{"key":"ref_76","unstructured":"(2023, August 24). GPC3-Directed CAR-T in the Treatment Amongst Subjects with Advanced Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05926726."},{"key":"ref_77","unstructured":"(2023, August 24). Study of GPC-3 CAR-T Cells in Treating with Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05620706."},{"key":"ref_78","unstructured":"(2023, August 24). To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05783570."},{"key":"ref_79","unstructured":"(2023, August 24). BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05120271."},{"key":"ref_80","unstructured":"(2023, August 24). GPC3-CAR-T Cells for Immunotherapy of Cancer with GPC3 Expression, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03198546."},{"key":"ref_81","unstructured":"(2023, August 24). Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04951141."},{"key":"ref_82","unstructured":"(2023, August 24). NKG2D-Based CAR T-Cells Immunotherapy for Patient with r\/r NKG2DL+ Solid Tumors, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05131763."},{"key":"ref_83","unstructured":"(2023, August 24). IMC001 for Clinical Research on Advanced Digestive System Malignancie, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05028933."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1158\/1535-7163.MCT-20-1025","article-title":"Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice","volume":"21","author":"Chen","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Safran, H., Druta, M., Morse, M., Lynce, F., Pintova, S., Almhanna, K., Weiss, D., Gianella-Borradori, A., Ogita, Y., and Morley, R. (and, January 10\u201315). Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)\/CD3 bispecific antibody, in patients with advanced solid tumors [abstract]. Proceedings of the American Association for Cancer Research Annual Meeting 2021, Philadelphia, PA, USA.","DOI":"10.1158\/1538-7445.AM2021-CT111"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"206","DOI":"10.14701\/ahbps.2021.25.2.206","article-title":"Adjuvant therapy using ex vivo-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study","volume":"25","author":"Kim","year":"2021","journal-title":"Ann. Hepatobiliary Pancreat. Surg."},{"key":"ref_88","unstructured":"(2023, August 24). Single-Arm, Open-Label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05845502."},{"key":"ref_89","unstructured":"(2023, August 24). CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02839954."},{"key":"ref_90","unstructured":"(2023, August 24). Safety and Efficacy of Allogeneic NK Cells Therapy in Patients with Advanced Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04162158."},{"key":"ref_91","unstructured":"(2023, August 24). Camrelizumab in Combination with Apatinib Plus NK Cell for Advanced HCC, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05171309."},{"key":"ref_92","unstructured":"(2023, August 24). Clinical Efficacy and Safety of NKT Cell Infusion in Patients with Advanced Solid Tumor, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02562963."},{"key":"ref_93","unstructured":"(2023, August 24). Natural Killer (NK) Cell Therapy in Locally Advanced HCC, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05040438."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Stemmer, S.M., Manojlovic, N.S., Marinca, M.V., Petrov, P., Cherciu, N., Ganea, D., Ciuleanu, T.E., Pusca, I.A., Beg, M.S., and Purcell, W.T. (2021). Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. Cancers, 13.","DOI":"10.3390\/cancers13020187"},{"key":"ref_96","unstructured":"(2023, August 24). Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Cirrhosis (LIVERATION), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05201404."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1078-0432.CCR-05-2856","article-title":"A phase I\/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides","volume":"12","author":"Butterfield","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e1129483","DOI":"10.1080\/2162402X.2015.1129483","article-title":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","volume":"5","author":"Sawada","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_99","unstructured":"(2023, August 24). Personalized Cancer Vaccine in Egyptian Cancer Patients (PROVE), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05059821."},{"key":"ref_100","unstructured":"(2023, August 24). Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases from CRC, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04912765."},{"key":"ref_101","unstructured":"(2023, August 24). A Clinical Study of mRNA Vaccine (ABOR2014\/IPM511) in Patients with Advanced Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05981066."},{"key":"ref_102","unstructured":"(2023, August 24). Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05738447."},{"key":"ref_103","unstructured":"(2023, August 24). GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04251117."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13287-022-02776-5","article-title":"Drug metabolic activity is a critical cell-intrinsic determinant for selection of hepatocytes during long-term culture","volume":"13","author":"Akiyama","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.biopha.2018.01.002","article-title":"Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity","volume":"98","author":"Li","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Zhao, Q., Zheng, B., Meng, S., Xu, Y., Guo, J., Chen, L.J., Xiao, J., Zhang, W., Tan, Z.R., and Tang, J. (2019). Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Biomed. Pharmacother., 114.","DOI":"10.1016\/j.biopha.2019.108864"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.canlet.2015.11.034","article-title":"MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS\/RAF\/ERK signaling pathways","volume":"371","author":"Xu","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"De Lorenzo, S., Tovoli, F., and Trevisani, F. (2022). Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14194616"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Yang, Z., Suda, G., Maehara, O., Ohara, M., Yoda, T., Sasaki, T., Kohya, R., Yoshida, S., Hosoda, S., and Tokuchi, Y. (2023). Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15030593"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Ding, J., and Wen, Z. (2021). Survival improvement and prognosis for hepatocellular carcinoma: Analysis of the SEER database. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08904-3"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/2\/1259\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:11Z","timestamp":1760103971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/2\/1259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":110,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25021259"],"URL":"https:\/\/doi.org\/10.3390\/ijms25021259","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}